Skip to content

Intraoperative single escitalopram ketamine vein or intranasal for cesarean delivery quality of maternal postpartum depression and postpartum recovery: a prospectie, randomized double-blind study

Intraoperative single escitalopram ketamine vein or intranasal for cesarean delivery quality of maternal postpartum depression and postpartum recovery: a prospectie, randomized double-blind study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075062
Enrollment
Unknown
Registered
2023-08-24
Start date
2023-08-12
Completion date
Unknown
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean delivery quality of maternal postpartum depression and postpartum recovery

Interventions

Group C:Give equal intranasal saline iv + amount of saline
Group S1:Escitalopram ketamine 0.3 mg/kg intravenous(Escitalopram ketamine concentration of 2 mg/ml) + amount of intranasal saline solution
Group S2:Escitalopram intranasal ketamine 0.6 mg/kg (escitalopram ketamine concentration of 25 mg/ml) + amount of saline iv

Sponsors

Fuyang city people's hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) aged 20-40 maternal ; (2) the American society of anesthesiologists ASA I - II; (3) the operation time is less than 2 h operation patients undergoing elective cesarean delivery; (4) no long-term application of analgesia, sedation, previous history of anti-anxiety drugs; (5) informed consent, volunteered for the experiment, and sign the informed consent. (6) BMI < 40 kg/m ~ 2

Exclusion criteria

Exclusion criteria: (1) patients with known allergic to escitalopram ketamine; Have a blood pressure or intracranial pressure in patients with serious risks; (2) puncture contraindications intra-spinal canal; Spinal canal anesthesia losers; (3) BMI > 40 kg/m ~ 2; (4) any serious systemic organ diseases (heart/liver/kidney), nervous system disease (cerebral palsy, autism, etc.), or a combination of drugs or other patients with inhibitors of the central nervous system; (4) control of poor or untreated hypertensive patients (arterial blood pressure is greater than 180/100 mg), preeclampsia and eclampsia. (5) without treatment or therapy in patients with hyperthyroidism (6) communication disorders, cognitive dysfunction, patients with a history of mental illness; (7) the researchers think that is unfavorable to the subjects of this study.

Design outcomes

Primary

MeasureTime frame
After the surgery 24 h, 48h self-test Edinburgh postpartum depression scale (EPDS) score;After 24 h,48hsleep assessment scale(RCSQ);After 24 h,The quality of life score(QOR-15);After 48 h,The quality of life score(QOR-15);

Secondary

MeasureTime frame
Home when T0,before broken umbilical T1, give 5 min after esketamine T2, give 10 min after esketamine T3, given esketamine 20 min after T4, give 30 min after esketamine T5 and T6 at the end of the operation of systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), HR, SPO2 %;Postoperative VAS score (after 6 h, 12 h, 24 h, 48 h);Intraoperative norepinephrine vascular active drug usage, etc;Sufentanil postoperative analgesia drug usage, etc;Intraoperative and postoperative adverse reactions (nausea, vomiting, peritoneal pull reactions, dizziness, headaches, dream, illusion, difficulty breathing, chest tightness, diplopia, discharge, etc.) and adverse events (low blood pressure, high blood pressure, hypoxemia, etc.);Ramsay score;Ropivacaine hydrochloride amount ??Plane of lumbar anesthesia;Number of ward remedial analgesia (diclofenac sodium) usage;Intraoperative uterine smooth muscle contraction agent usage;

Countries

china

Contacts

Public ContactYong NIu

Fuyang city people's hospital

15956840690@163.com+86 159 5684 0690

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026